UK 356618MMP-3 inhibitor,potent and selective CAS# 230961-08-7 |
- Laminin (925-933)
Catalog No.:BCC1015
CAS No.:110590-60-8
- Epidermal Growth Factor Receptor Peptide (985-996)
Catalog No.:BCC1014
CAS No.:96249-43-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 230961-08-7 | SDF | Download SDF |
| PubChem ID | 10370504 | Appearance | Powder |
| Formula | C34H43N3O4 | M.Wt | 557.72 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 25 mg/mL (44.83 mM; Need ultrasonic and warming) | ||
| Chemical Name | (2R)-N-[(2S)-3,3-dimethyl-1-oxo-1-[[(1R)-1-phenylethyl]amino]butan-2-yl]-N'-hydroxy-2-[3-(3-methyl-4-phenylphenyl)propyl]butanediamide | ||
| SMILES | CC1=C(C=CC(=C1)CCCC(CC(=O)NO)C(=O)NC(C(=O)NC(C)C2=CC=CC=C2)C(C)(C)C)C3=CC=CC=C3 | ||
| Standard InChIKey | JJHRUUKMPWUYIB-HVOSOHGQSA-N | ||
| Standard InChI | InChI=1S/C34H43N3O4/c1-23-21-25(19-20-29(23)27-16-10-7-11-17-27)13-12-18-28(22-30(38)37-41)32(39)36-31(34(3,4)5)33(40)35-24(2)26-14-8-6-9-15-26/h6-11,14-17,19-21,24,28,31,41H,12-13,18,22H2,1-5H3,(H,35,40)(H,36,39)(H,37,38)/t24-,28-,31-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent and selective inhibitor of MMP-3 (IC50 = 5.9 nM). Displays selectivity over a range of MMPs (IC50 values are 73, 840, 1790, 1900 and 51000 for MMP-13, MMP-9, MMP-2, MMP-14 and MMP-1 respectively). |
UK 356618 Dilution Calculator
UK 356618 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.793 mL | 8.9651 mL | 17.9301 mL | 35.8603 mL | 44.8254 mL |
| 5 mM | 0.3586 mL | 1.793 mL | 3.586 mL | 7.1721 mL | 8.9651 mL |
| 10 mM | 0.1793 mL | 0.8965 mL | 1.793 mL | 3.586 mL | 4.4825 mL |
| 50 mM | 0.0359 mL | 0.1793 mL | 0.3586 mL | 0.7172 mL | 0.8965 mL |
| 100 mM | 0.0179 mL | 0.0897 mL | 0.1793 mL | 0.3586 mL | 0.4483 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
UK 356618 is a selective and potent inhibitor of MMP-3 that shows selectivity over a range of MMPs.
- Neuropeptide SF (mouse, rat)
Catalog No.:BCC6054
CAS No.:230960-31-3
- Chebulagic acid
Catalog No.:BCN3262
CAS No.:23094-71-5
- Corilagin
Catalog No.:BCN2322
CAS No.:23094-69-1
- 2-amino-3-(3-bromo-5-chloro-4-hydroxyphenyl)propanoic acid
Catalog No.:BCN8284
CAS No.:
- Sitosteryl palmitate
Catalog No.:BCN5078
CAS No.:2308-85-2
- Xylazine HCl
Catalog No.:BCC4341
CAS No.:23076-35-9
- 4-Amino-N-methylphthalimide
Catalog No.:BCC8686
CAS No.:2307-00-8
- PD 102807
Catalog No.:BCC7145
CAS No.:23062-91-1
- Eurycomalactone
Catalog No.:BCN3108
CAS No.:23062-24-0
- Varenicline Hydrochloride
Catalog No.:BCC4156
CAS No.:230615-23-3
- Sinensetin
Catalog No.:BCN6356
CAS No.:2306-27-6
- (-)-Sophoranone
Catalog No.:BCN7162
CAS No.:23057-55-8
- UK 370106
Catalog No.:BCC2379
CAS No.:230961-21-4
- Fumagillin
Catalog No.:BCC2347
CAS No.:23110-15-8
- Methylxanthoxylin
Catalog No.:BCC8212
CAS No.:23121-32-6
- Lapatinib
Catalog No.:BCC3633
CAS No.:231277-92-2
- N-[3-Chloro-4-(3-fluorobenzyloxy)phenyl]-6-iodoquinazolin-4-amine
Catalog No.:BCC9068
CAS No.:231278-20-9
- 5-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)furan-2-carbaldehyde
Catalog No.:BCC8719
CAS No.:231278-84-5
- Mudanpioside H
Catalog No.:BCC9049
CAS No.:231280-71-0
- 6'-O-xylosyl-glycitin
Catalog No.:BCN8169
CAS No.:231288-18-9
- Tectorigenin 7-O-xylosylglucoside
Catalog No.:BCN2903
CAS No.:231288-19-0
- Heveaflavone
Catalog No.:BCN5079
CAS No.:23132-13-0
- Physalin B
Catalog No.:BCN7921
CAS No.:23133-56-4
- Strictosamide
Catalog No.:BCN5080
CAS No.:23141-25-5
Conceptualizing the health and well-being impacts of social enterprise: a UK-based study.[Pubmed:28369450]
Health Promot Int. 2018 Oct 1;33(5):748-759.
Social enterprises-businesses that work for social benefit rather than for the maximization of financial returns to shareholders or owners-could potentially prove to be an innovative and sustainable way of tackling 'upstream' social determinants of health. However, empirical work focusing upon how, and to what extent, social enterprise-led activity may impact upon health and well-being is still relatively scarce. This study examines how social enterprises portray their impact, and how such impacts may be considered in health and well-being terms. Through analysing evaluative reports of the work of social enterprises in Scotland (n = 17) utilizing a 'process coding' method, we investigate both the self-reported impacts of the work of social enterprises and the mechanisms by which these are said to be derived. Revisiting previous conceptualizations in the extant literature, this work allows us to present an 'empirically-informed' conceptual model of the health and well-being impacts of social enterprise-led activity, and thus presents a significant advance on previous hypothetical, theoretically-based conceptualizations. It is considered that these findings further improve our overall knowledge of ways in which social enterprise and other parts of the third sector could be considered as potentially valuable 'non-obvious' public health actors.
Cardiovascular causes of maternal sudden death. Sudden arrhythmic death syndrome is leading cause in UK.[Pubmed:28371698]
Eur J Obstet Gynecol Reprod Biol. 2017 May;212:155-159.
OBJECTIVE: This study aims to determine the causes of sudden cardiac death during pregnancy and in the postpartum period and patients' characteristics. There are few studies in the literature. METHODS: Eighty cases of sudden unexpected death due to cardiac causes in relation to pregnancy and postpartum period in a database of 4678 patients were found and examined macroscopically and microscopically. RESULTS: The mean age was 30+/-7 years with a range from 16 to 43 years. About 30% were 35 years old or older; 50% of deaths occurred during pregnancy and 50% during the postpartum period. About 59.18% were obese or overweight where body mass index data were available. The leading causes of death were sudden arrhythmic death syndrome (SADS) (53.75%) and cardiomyopathies (13.80%). Other causes include dissection of aorta or its branches (8.75%), congenital heart disease (2.50%) and valvular disease (3.75%). CONCLUSION: This study highlights sudden cardiac death in pregnancy or in the postpartum period, which is mainly due to SADS with underlying channelopathies and cardiomyopathy. We wish to raise awareness of these frequently under-recognised entities in maternal deaths and the need of cardiological screening of the family as a result of the diagnosis.
Food insecurity and socio-demographic characteristics in two UK ethnic groups: an analysis of women in the Born in Bradford cohort.[Pubmed:28369526]
J Public Health (Oxf). 2018 Mar 1;40(1):32-40.
Background: The use of foodbanks has risen sharply in the UK; however, the epidemiology of UK food insecurity is undeveloped. This study contributes to the field by analysing socio-demographic risk factors for food insecurity in a female, ethnically diverse population. Methods: Data from the Born in Bradford (BiB) cohort were matched with data on food insecurity from the nested BiB1000 study (N = 1280). Logistic regression was used to model food insecurity in relation to ethnicity and socio-demographic factors. Results: Food insecurity, reported by 13.98% of the sample, was more likely among White British than Pakistani women (crude Odds Ratio (OR) 1.94, 95% CI: 1.37; 2.74, adjusted OR 2.37, 95% CI: 1.57; 3.59). In fully adjusted analyses, food insecurity was associated with a range of socio-economic measures, particularly the receipt of mean-tested benefits (adjusted OR 2.11, 95% CI: 1.41; 3.15) and perception of financial insecurity (adjusted OR 8.91, 95% CI: 4.14; 19.16 for finding it difficult/very difficult compared to living comfortably). Conclusions: The finding that food insecurity prevalence may be higher than previously thought and that food insecurity is highly associated with socio-economic status, notably benefit receipt, is a cause for concern necessitating an urgent policy response.
Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1).[Pubmed:11229774]
Bioorg Med Chem Lett. 2001 Feb 26;11(4):571-4.
Structure activity relationships are described for a series of succinyl hydroxamic acids 4a-o as potent and selective inhibitors of matrix metalloprotease-3 (stromelysin-1). Optimisation of P1' and P3' groups gave compound 4j (MMP-3 IC50=5.9nM) which was >140-fold less potent against MMP-1 (IC50=51,000nM), MMP-2 (IC50=1790nM), MMP-9 (IC50=840nM) and MMP-14 (IC50=1900nM).
